explore -WSS

explore

author：hotspot 2025-10-01 22:57:42 - browse：7

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

hotspot

WSS

Methadone doses haven’t kept up in the age of fentanyl

For Cytokinetics, FDA rejection of heart drug would help, not hinder

The best solution to the drug shortages problem

Schizophrenia gene found to be linked to cells' energy dysfunction

Dozens dead from Maui wildfires: What we know about the victims

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

hotspot

explore

Wikipedia

Tori Bowie and the unacceptable rates of Black maternal death

Why failed clinical trials don’t always spell doom for a new drug

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Hepatitis C has a cure — but many Americans still lack access to it

Emergent cuts jobs, executive role in business shake

The high cost of giving birth even with insurance

Senators push IRS to launch nonprofit hospital probe

Peter Hotez and the public health issue of online harassment

Maui wildfire now ranks as the fifth

entertainment

Wegovy’s successful heart trial raises vital question about weight loss

Be careful with at

Idaho college killings prosecutors challenge defense's grand jury claims

Surge in Apellis stock fueled by confidence in safety of its eye drug

What to know about the judge who will handle the Trump case

Megan Rapinoe shares emotional post following US Women's World Cup exit

knowledge

leisure time

hotspot

knowledge